The Food and Drug Administration (FDA) has approved Xeomin for temporary improvement of moderate to severe glabellar lines. This alternative to Botox and Dysport has been used for many years in 14 European countries under the name Bocouture.
Xeomin is made by Merz, a company known for their filler Radiesse. Xeomin was already approved by FDA in 2010 for certain neurological conditions.
There have been many claims of superiority of many products used for wrinkle treatments. However, there is no significant difference in any of them from clinical and practical point of view.
The studies have shown that two major claims are of no importance. First, if given in comparable doses and similar concentration, all products diffuse at the same rate and at the same distance from the point of injection. Second, the presence or absence of proteins in product is immaterial since these are immediately neutralized after injection.
Merz expects also an approval for new hyaluronic acid filler(s) that have been used in Europe for few years. Once approved, the company will become the main competitor on the aesthetic market in the US.